LEXX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LEXX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Lexaria Bioscience's Cash Ratio for the quarter that ended in Feb. 2024 was 58.45.
Lexaria Bioscience has a Cash Ratio of 58.45. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Lexaria Bioscience's Cash Ratio or its related term are showing as below:
During the past 13 years, Lexaria Bioscience's highest Cash Ratio was 76.81. The lowest was 0.11. And the median was 15.78.
The historical data trend for Lexaria Bioscience's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexaria Bioscience Annual Data | |||||||||||||||||||||
Trend | Oct13 | Aug15 | Aug16 | Aug17 | Aug18 | Aug19 | Aug20 | Aug21 | Aug22 | Aug23 | |||||||||||
Cash Ratio | Get a 7-Day Free Trial | 7.29 | 5.81 | 76.81 | 31.76 | 5.51 |
Lexaria Bioscience Quarterly Data | ||||||||||||||||||||
May19 | Aug19 | Nov19 | Feb20 | May20 | Aug20 | Nov20 | Feb21 | May21 | Aug21 | Nov21 | Feb22 | May22 | Aug22 | Nov22 | Feb23 | May23 | Aug23 | Nov23 | Feb24 | |
Cash Ratio | Get a 7-Day Free Trial | 15.87 | 3.25 | 5.51 | 16.22 | 58.45 |
For the Biotechnology subindustry, Lexaria Bioscience's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's Cash Ratio falls into.
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Lexaria Bioscience's Cash Ratio for the fiscal year that ended in Aug. 2023 is calculated as:
Cash Ratio (A: Aug. 2023 ) | = | Cash, Cash Equivalents, Marketable Securities | / | Total Current Liabilities |
= | 1.478 | / | 0.268 | |
= | 5.51 |
Lexaria Bioscience's Cash Ratio for the quarter that ended in Feb. 2024 is calculated as:
Cash Ratio (Q: Feb. 2024 ) | = | Cash, Cash Equivalents, Marketable Securities | / | Total Current Liabilities |
= | 4.793 | / | 0.082 | |
= | 58.45 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexaria Bioscience (NAS:LEXX) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Thank you for viewing the detailed overview of Lexaria Bioscience's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Catherine C. Turkel | director | 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612 |
Gregory Downey | officer: Chief Financial Officer | 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7 |
Christopher Bunka | director, 10 percent owner, officer: CEO | 1924 BIRKDALE AVE, KELOWNA A1 V1P1R7 |
Vanessa Carle | officer: Secretary | 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7 |
Reese Albert L Jr | director | |
Brian W. Quigley | director | 100 740 MCCURDY ROAD, KELOWNA A1 23230 |
William Edward Mckechnie | director | 305 MARGARET AVENUE, KITCHENER A6 N2H 6S4 |
Allan Horst Spissinger | officer: CFO | 8131 198A STREET, LANGLEY A1 V2Y 1Y6 |
John Martin Docherty | director, 10 percent owner | 23 MIKELEN DRIVE, PORT PERRY A6 L9L 1V1 |
Baljinder Bhullar | director, officer: CFO | 604 - 700 WEST PENDER, VANCOUVER A1 V6C 1G8 |
Nicholas W Baxter | director | 220 SPRINGFIELD ROAD, ABERDEEN, ABERDEENSHIRE, SCOTLAND X0 AB15 6AU |
Dustin Arthur Elford | director | 888 - 609 WEST HASTINGS STREET, VANCOUVER A1 V6B 4W4 |
Thomas James Ihrke | officer: Sr. VP, Business Development | 38 KRIER LANE, MOUNT PLEASANT SC 29464 |
David Demartini | director, 10 percent owner | 11714 SPRIGGS WAY, HOUSTON TX 77024 |
Leonard Macmillan | director, officer: Vice President - Corp Develop | SUITE 302, 125A - 1030 DENMAN STREET, VANCOUVER A1 V6G 2M6 |
From GuruFocus
By ACCESSWIRE • 11-28-2023
By ACCESSWIRE ACCESSWIRE • 04-20-2023
By ACCESSWIRE • 09-21-2023
By ACCESSWIRE • 07-28-2023
By ACCESSWIRE ACCESSWIRE • 05-11-2023
By ACCESSWIRE • 08-30-2023
By ACCESSWIRE • 09-29-2023
By ACCESSWIRE • 10-12-2023
By ACCESSWIRE ACCESSWIRE • 06-12-2023
By ACCESSWIRE ACCESSWIRE • 02-21-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.